Sacubitril/valsartan, marketed as Entresto, is a medication used to treat heart failure with reduced ejection fraction [1]. The development and approval of generic versions of Entresto are subject to patent protections and regulatory processes.
When Can Generic Entresto Be Available?
The availability of generic Entresto depends on the expiration of its patents and any exclusivities granted by regulatory bodies like the U.S. Food and Drug Administration (FDA). DrugPatentWatch.com tracks these patents and provides timelines for potential generic entry [2]. Typically, once patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions of the drug.
What Patents Protect Entresto?
Novartis, the manufacturer of Entresto, holds several patents covering the drug's composition of matter, manufacturing processes, and methods of use [2]. These patents are crucial for maintaining market exclusivity. Challenges to these patents can occur, potentially leading to earlier generic availability [3].
What Are the Regulatory Hurdles for Generic Entresto?
For a generic version of Entresto to be approved, it must demonstrate bioequivalence to the brand-name drug, meaning it delivers the same amount of active ingredient into a patient's bloodstream over the same period [4]. The FDA reviews this data, along with manufacturing information, to ensure safety and efficacy [4].
Who Are the Potential Generic Competitors for Entresto?
Several pharmaceutical companies are involved in the development and potential manufacturing of generic versions of sacubitril/valsartan [5]. These companies often file abbreviated new drug applications (ANDAs) with the FDA to gain approval for their generic products [3]. Information on companies actively pursuing generic Entresto can be found through specialized pharmaceutical intelligence platforms [5].
How Does Generic Entresto Compare to the Brand-Name Drug?
Generic medications are required to be therapeutically equivalent to their brand-name counterparts [4]. This means that generic Entresto, once approved, will contain the same active ingredients (sacubitril and valsartan) in the same dosage form and strength, and will perform in the same way in the body. The primary difference is usually in the inactive ingredients and, significantly, the cost [4].
What is the Expected Cost of Generic Entresto?
Generic drugs are typically priced lower than their brand-name equivalents due to reduced research and development costs and increased market competition [4]. The exact pricing for generic Entresto will be determined by the manufacturers once it becomes available and will likely be subject to market dynamics.
What Medical Conditions Does Entresto Treat?
Entresto is prescribed for patients with symptomatic chronic heart failure with left ventricular systolic dysfunction [1]. It works by improving the heart's ability to pump blood and reducing the strain on the heart [1].
Sources:
[1] National Institutes of Health. "Sacubitril/Valsartan." MedlinePlus.
[2] DrugPatentWatch.com. "Sacubitril/Valsartan Patent Information."
[3] U.S. Food and Drug Administration. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations."
[4] U.S. Food and Drug Administration. "Generic Drugs."
[5] Informa Pharma Intelligence. "Sacubitril/Valsartan Generic Landscape."